Siemens Healthineers übernimmt Novartis-Geschäft im Bereich Krebsdiagnostik | 25.08.24

Siemens Healthineers has developed a new pharmaceutical technology using radioactive chemicals for credit diagnostics.

The German Medizintechnik-Konzern would spend more than 200 million euros on new investments, which the “Financial Times” (“FT”) in the future a commotion with the trusted persons write. The transaction itself can bring both the best results. It is so that the years are completed.

Siemens Healthineers has entered the “FT” market, while the US is expanding its PET Radiopharmaceutical arm with the expansion into Europe.

/mis

LONDON (dpa-AFX)